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Abstract
Background: The role of pathogen specific cellular immune responses against the eliciting pathogen in development
of post-infectious chronic fatigue syndrome (PI-CFS) is not known and such studies are difficult to perform. The aim of
this study was to evaluate specific anti-Giardia cellular immunity in cases that developed CFS after Giardia infection
compared to cases that recovered well. Patients reporting chronic fatigue in a questionnaire study three years after a
Giardia outbreak were clinically evaluated five years after the outbreak and grouped according to Fukuda criteria for
CFS and idiopathic chronic fatigue. Giardia specific immune responses were evaluated in 39 of these patients by
proliferation assay, T cell activation and cytokine release analysis. 20 Giardia exposed non-fatigued individuals and 10
healthy unexposed individuals were recruited as controls.
Results: Patients were clinically classified into CFS (n = 15), idiopathic chronic fatigue (n = 5), fatigue from other causes
(n = 9) and recovered from fatigue (n = 10). There were statistically significant antigen specific differences between
these Giardia exposed groups and unexposed controls. However, we did not find differences between the Giardia
exposed fatigue classification groups with regard to CD4 T cell activation, proliferation or cytokine levels in 6 days
cultured PBMCs. Interestingly, sCD40L was increased in patients with PI-CFS and other persons with fatigue after
Giardia infection compared to the non-fatigued group, and correlated well with fatigue levels at the time of sampling.
Conclusion: Our data show antigen specific cellular immune responses in the groups previously exposed to Giardia
and increased sCD40L in fatigued patients.
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Background
The causes and underlying mechanisms for development
of chronic fatigue syndrome (CFS) remain unresolved.
In some cases the condition is elicited by an infection,
with mononucleosis due to Epstein Barr infection (EBV)
being the most well-known [1]. However, it is also de-
scribed to occur following a number of other infections
[1]. When the onset of CFS is associated with an acute
infection, it can be termed post-infectious (PI) and many
researchers have focused on measures of the immune
system in the quest to understand mechanisms and
identify biomarkers [2–6].
It is likely that the nature of the host reaction to the
specific eliciting pathogens is implicated in development
of PI-CFS. This is inherently difficult to study, as
patients often present at a late stage where it is difficult
to ascertain the specific eliciting pathogen and it is chal-
lenging to gather enough patients of a specific etiology
to perform such studies.
An opportunity to investigate potential differences in
the magnitude or quality of host responses towards the
eliciting pathogen arose when a fraction of Giardia
assemblage B infected persons developed post-infectious
chronic fatigue (CF) after a large waterborne outbreak in
Bergen, Norway in 2004 [7]. Most of these individuals
also had co-morbid functional gastrointestinal disorders
(FGID) elicited by the Giardia infection. Post-giardiasis
chronic fatigue had not previously been described in the
literature. It was the clinical follow-up of referred
patients with persisting symptoms after successful
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Giardia treatment that informed the choice of question-
naires which were sent to all laboratory-confirmed cases
two years after the outbreak [8], and at three years when
we also included a control group [9]. Severity of the pri-
mary Giardia illness was a risk factor for developing
both FGID and CF [10]. It became clear that chronic
fatigue symptoms were four times more prevalent in the
Giardia exposed group compared to controls [9]. Five
years after the outbreak, PI-CFS was found in 42% (22/53)
among patients who had reported chronic fatigue in the
questionnaire three year after the outbreak [11].
In the present study we aimed to evaluate if Giardia
specific immune responses such as proliferative capacity,
CD4 T cell activation and cytokine profiles, were associ-
ated with development of CFS in this group of carefully
clinically characterized persons. Responses were com-
pared with a Giardia exposed group without fatigue, and
with Giardia-naïve controls, in order to allow interpret-
ation of the data with respect to Giardia exposure and
specificity of the responses.
Methods
Study populations
Participants were recruited based on responses to a ques-
tionnaire mailed three years (in 2007) after the outbreak
to all persons with laboratory confirmed giardiasis during
the outbreak [9]. Patients who reported chronic fatigue in
this questionnaire were invited to participate in a thorough
clinical evaluation and screening two years later (in 2009).
Fifty-three individuals agreed to participate, and went
through a clinical evaluation by specialists in internal medi-
cine, psychiatry and neurology. They were evaluated for
CFS or idiopathic chronic fatigue (ICF) according to the
1994 Fukuda criteria [12]. Those fulfilling the criteria, and
had an onset of symptoms related to the Giardia infection,
were categorized as PI-CSF or PI-ICF. Patients with sleep
apnea syndrome, significant depression or anxiety disorders
that could plausibly explain their fatigue were termed
“fatigue other cause”. Individuals who had recovered well
from the fatigue condition they had reported in the
questionnaire two years previously were termed “fatigue
recovered”. Five patients were excluded from this study
after clinical evaluation (Fig. 1).
Two control groups were recruited; 22 individuals with
normal fatigue score (=11) in the 2007 questionnaire
(exposed, no-PI-fatigue group), and 10 healthy individuals
not affected by the outbreak and without particular fatigue
or abdominal symptoms (unexposed healthy controls)
(Fig. 1). All participants were HIV negative and were not
taking immunomodulatory medications or antibiotics.
Sampling and questionnaires
Participants were screened with a battery of routine
blood tests and a magnetic resonance imaging (MRI)
Fig. 1 Selection of the patient poulation for the present study
Hanevik et al. BMC Immunology  (2017) 18:5 Page 2 of 8
brain scan. Blood samples were taken between 08 am
and 09 am after overnight fast and analyzed in parallel
during the same period. Immunophenotyping results
from these investigations have been reported previously
[13]. Fecal samples were obtained and screened with
microscopic examination and Giardia 18S PCR [14] of
feces to rule out chronic giardiasis.
A total of 69 of the study participants underwent
clinical characterization and were subject to one or more
of the Giardia-specific immune response analyses pre-
sented in this paper. Some assays could not be done in
all patients due to limited cell numbers (Fig. 1). Sam-
pling and assays were stratified across groups and
samples were blinded to laboratory personnel to avoid
analytical bias. The severity of fatigue at the time of
sampling was evaluated in all participants by the Fatigue
Questionnaire [15], a validated set of 11 questions
addressing different aspects of fatigue. Comorbid ab-
dominal symptoms were recorded by the commonly
used Rome II questionnaire [16].
Antigens
The Giardia antigens used in this study were made from
culturing Giardia assemblage A strain WB-C6 (ATCC
50803) and assemblage B strain GS/M (ATCC 50581) in
Diamond’s TYI-S-33 medium supplemented with bile as
described previously[17]. Trophozoites were washed in
PBS, treeze-thawed, then sonicated for 1 min at 20 W.
After sentrifugation at 13000 x g, the supernatant
containing soluble Giardia proteins was removed, and
protein content was measured by the BCA protein assay
kit (Pierce). Pilot testing showed that 10ug/mL of this
mixed soluble Giardia antigens resulted in robust T cell
responses and little background stimulation.
For the proliferation assay also a sterile filtered
Candida albicans protein extract (403 skin prick test
[Allergopharma]; 10 000 BU/mL), were added as an ex-
ploratory antigen and anti-CD3 + anti-CD28 as a control
of T cell activation. Positive antigen controls were tuber-
culin purified protein derivate (PPD) (Statens Serum
Institut) and Salmonella typhi LPS in all assays. Several
concentrations were tested in pilot studies of all stimula-
tion antigens and positive controls to optimize the assay.
PBMC acquisition and antigen-specifc immunity assays
Peripheral blood mononuclear cells (PBMC) were iso-
lated from BD Vacutainer Na-citrate CPT tubes (BD,
Franklin Lakes, NJ, USA) by density gradient separation.
After harvesting, the PBMC were washed twice in PBS
and were cultured in the presence or absence of investi-
gational or control antigens at 37 °C in a humidified
atmosphere of 5% CO2for six days in X-vivo 15 serum-
free culture medium supplemented with L-glutamin,
gentamicin, and phenol red (BioWhittaker).Proliferative
responses were measured in triplicates of stimulated
cultured cells by adding 3H-thymidine (Amersham Inter-
national) after five days, and harvesting 18 h later.
IIncorporated radioactivity was analysed by liquid
scintillation counting in a β-counter. Proliferation in
stimulated and unstimulated cultures was determined as
median counts per minute (cpm) of each triplicate.
Activation of T cells was evaluated after six days in
culture. 100 μL supernatants were carefully harvested
from wells of unstimulated and stimulated PBMCs and
frozen at −80 °C for later cytokine analysis. The cultured
cells were then analysed by flow cytometric measurement
of activated T cell subsets as published previously [17].
Briefly, after washing with PBS, the cultured cell suspen-
sions (50 μL) were stained for 30 min in the dark with
combination of 5 fluorescent dyes: CD3-ECD (Beckman
Coulter), CD8a-FITC and CD4-PerCP/Cy5.5 and the acti-
vation markers CD26-PE and CD25-PE/Cy7 (BioLegend).
After staining, cells were washed once, resuspended in
PBS-paraformaldehyde solution (1%) and analyzed the
same day using a Beckman Coulter Cytomics FC 500
MPL flow cytometer. In a typical acquisition 7×104 lym-
phocytes (min 2.3 ×104, max 1.7 ×105) were collected.
The collected data were analyzed with FlowJo 7.6 software
(Tree Star Inc, Ashland, OR, USA). Background responses
in unstimulated cultures were adjusted for by subtracting
these from responses in stimulated cultures.
Supernatants were kept frozen until analysis in three
Bio-Plex assays (Bio-Rad Laboratories Inc., Hercules,
CA, USA) for IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-
9, IL-10, IL-13, IL-17A, IL-22, soluble (s) sCD40L,
macrophage inflammatory protein 1 alpha (MIP-1α),
MIP-1β, TGFβ1, TGFβ2, TGFβ3 and granulocyte macro-
phage colony-stimulation factor (GM-CSF) according to
the manufacturer’s instructions. The cytokines TGFβ1,
TGFβ2, TGFβ3 were analyzed in unstimulated and
Giardia antigen stimulated cultures only. Observed con-
centrations (pg/ml) within the standard range were used
for analysis. Values above the limit of quantitation were
set to the highest value in the standard range, and values
below this range were set to zero. For analytes where
less than 50% of values were within range, further
analyses were not done.
For both flow cytometric and cytokine assays, back-
ground responses in unstimulated cultures were sub-
tracted from those in stimulated cultures for each
participant. In some cases this gave negative values in the
cytokine assay which were kept in the statistical analyses
and interpreted as stimulant-induced decrease in produc-
tion or increase in consumption of the relevant analyte.
Statistical analysis
Unless otherwise stated the data are presented as
median (standard deviation (SD)). Chi-squared tests
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were used for categorical comparisons between groups.
Linear regression analysis was used for correlation
between response parameters as well as fatigue scores
and sCD40L data. Comparison of T cell activation,
proliferation and cytokine data between exposed and
unexposed groups was done using the Mann Whitney U
test. The significance level was set at p <0.05. To reduce
false positive findings due to multiple comparisons
within the exposed groups, we used the Kruskal-Wallis
test across all exposed groups first, and further testing
between the no PI-fatigue and PI-CFS/PI-ICF groups
with Mann Whitney U test was only performed for
variables with a p value less than 0.05. IBM SPSS Statis-




Patients and controls were grouped according to their
clinical condition at the time of sampling. Data from 39
patients (median age 40.9 years (11.2) range 19–62,
females 74%), 20 exposed controls (median age 39.5
(9.3) range 27–66, females 75%) and 10 unexposed con-
trols (median age 43.3 (14.3) range 22–63, females 70%)
were analyzed in this study. There were no significant
differences in age (p = 0.06) or sex distribution (p = 0.61).
Fatigued patients were categorized according to their
clinical categories for analyses of antigen specific im-
mune responses (Table 1). ICF and CFS were combined
in the further analyses as they were seen as a common
phenotype with difference only in severity of symptoms.
The fatigue scores generally reflected the categorization
obtained by careful clinical evaluation with the cases of
CSF scoring higher than the ICF and fatigue by other
cause groups. The patients who had recovered well still
had a modestly elevated fatigue score compared to re-
cruited exposed and unexposed controls.
Giardia-induced proliferation of immunocompetent cells
PMBC proliferated well in response to all stimuli
included in this assay. A marked memory response was
seen in the Giardia exposed groups that showed signifi-
cantly stronger proliferation in response to the Giardia
lysates compared to the unexposed group (Table 2).
However, the proliferative responses to Giardia antigens
did not differ significantly between the fatigue categories
within the exposed group (Table 2). For the other
specific antigen controls we found neither a difference
with regard to previous exposure to Giardia, nor ac-
cording to fatigue sequels. There was a trend towards
decreased proliferation induced by the strong T cells
activator anti-CD3antiCD28 among the fatigued groups
compared to the no fatigued controls, but this did not
attain significance (Table 2).
Giardia-induced T cell expression of activation markers
Levels of activated CD4 T cells expressing CD25 and
CD26 were significantly elevated in Giardia exposed
groups compared to unexposed patients when stimu-
lated with both Giardia assemblage A and assemblage B
lysates (Table 3). The PPD and LPS control antigens
induced similar levels of activated CD4 T cells in both
exposed and unexposed groups. None of these stimuli
induced differences between the exposed participants
with or without fatigue sequels. The flow cytometric
responses correlated well with proliferation responses to
the same antigens with p <0.001 for assemblage A stimula-
tion and p = 0.001 for assemblage B stimulated cultures.
Giardia-induced release of soluble mediators
In Table 4 the results of cytokines and sCD40L are given
for levels of an array of cytokines and sCD40L in super-
natants of PBMC stimulated for six days with Giardia
assemblage B lysate. There were significant differences
for most of these, except IL-4, IL-2, TGFβ2 and TGFβ3
between the Giardia exposed and unexposed partici-
pants. The same pattern was seen, but with weaker
differences in responses to Giardia assemblage A. For
PPD there were smaller, but significant differences only
for IFNγ and sCD40L between exposed and unexposed
groups, while for LPS stimulated supernatants no differ-
ence was found (Additional file 1: Table S1).
In the analysis of Giardia antigen induced differences
in cytokine profiles with regard to fatigue outcome we
found only sCD40L to be significantly different within
exposed groups (KruskalWallis p = 0.03) and the PI-
CFS/PI-ICF groups having significantly elevated levels of
sCD40L compared to the no PI-fatigue groups (Table 4).
Also a significant difference was found when comparing













39.5 (9.3) 15 (75) 11 (1.3) 20
PI-CFS 47.0 (8.6) 11 (73) 22.0 (5.3) 15
PI-ICF 35.0 (8.9) 4 (80) 20.0 (3.1) 5
Fatigue other
cause
51.0 (15.6) 9 (100) 18.0 (5.1) 9
Recovered
from fatigue




39 (11.1) 7 (70) 11 (2.1) 10
Abbreviations: PI post-infectious, CFS chronic fatigue syndrome, ICF idiopathic
chronic fatigue
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the no-PI-fatigue group with the PI-CFS group (n = 14)
alone, and with the fatigue other cause group (p = 0.038),
but not with the recovered group. Interestingly, sCD40L
levels in supernatants correlated well with fatigue scores
(p = 0.001), shown in Fig. 2.
The antigen-specific immune responses were also ex-
plored with regard to co-morbidity with functional
gastrointestinal disorders, but significant correlations
were not found (data not shown).
Discussion
The data presented in this study confirm previous find-
ing of long term T cell memory responses towards
Giardia [17], and bring new data on cytokines profiles
elicited in this response. However, in the present study,
performed in a well-defined group of patients with clin-
ically observed post-infectious FGID and CFS five years
after a common eliciting infection, we did not identify
any differences in the antigen-specific cellular immunity
against the culprit infectious agent, in this case G.
lamblia. The higher levels of sCD40L in supernatants in
Giardia stimulated PBMCs from persons with PI-CFS
correlated well with fatigue scores, but could be unspe-
cific for PI-CFS as it was also found in persons reporting
fatigue that could be explained by other conditions. An
alternative explanation could be that also these could
have a component of Giardia induced fatigue, but they
did not fulfil the Fukuda criteria due to their other ill-
ness. As such, further investigation is warranted to
evaluate whether sCD40L might be a marker of fatigue
in general or a marker for PI-CFS. Alternatively, this
may be an effect related to Giardia exposure in all the
fatigued patients. Since we did not include a control
group of fatigued patients without Giardia exposure, we
cannot conclude firmly on these options.
The present study thus underlines the need to include
patient control groups where fatigue is a common symp-
tom in all studies looking for biomarkers of CFS. Our
study design, which included exposed groups with
fatigue, but not fulfilling the criteria for CFS/ICF allowed
for a more cautious interpretation. A previous study has
found that an increase in serum sCD40L eight hours
after exertion correlated with increases in physical
fatigue 48 h post-exertion [18]. Our data support that
CD40L, a co-stimulatory molecule which is found on a
variety of cells and promotes B cell maturation, could be
a marker of fatigue. Another study has suggested that
sCD40L can increase blood brain permeability in vivo,
Table 2 Immune responses against Giardia and control antigens as measured by 3H-thymidine proliferation assay
Exposed Unexposed p-values
Stimulation agent No PI-fatigue
controls (n = 19)
PI-CFS &
ICF (n = 19)
Fatigue other
cause (n = 9)
Recovered from
fatigue (n = 9)
Healthy controls
(n = 10)
Exposed n = 56)vs
unexposed (n = 10)
No PI-fatigue controls
(n= 19) vs PI-CFS/ICF
(n = 19)
Giardia ass A 10 μg/ml 12.8 (13.0) 15.3 (19.9) 20.3 (10.9) 15.1 (65.0) 3.5 (6.2) 0.001 ns*
Giardia ass B 10 μg/ml 12.2 (13.9) 13.3 (15.3) 23.3 (13.4) 15.3 (39.0) 3.5 (4.7) <0.001 ns*
Tuberculin (PPD)10
μg/ml
26.3 (34.1) 34.0 (47.5) 54.9 (84.5) 42.5 (23.2) 27.7 (27.0) ns ns*
LP S Stypi 1 μg/ml 21.5 (18.6) 14.4 (13.2) 38.2 (34.3) 21.9 (19.5) 17.7 (10.5) ns ns*
C albicans 10 μg/ml 7.0 (9.1) 5.8 (11.9) 10.0 (32.0) 14.6 (6.0) 11.0 (9.4) ns ns*
aCD3aCD28(pos ctr) 70.6 (35.4) 51.4 (33.0) 51.8 (44.1) 51.8 (63.9) 60.1 (39.8) ns ns*
*KruskalWallis test across all exposed groups was not significant (below p = 0.05). ns = not significant
Proliferation responses are expressed as median stimulation indices (counts per minute(cpm) in stimulated triplicate cultures divided by cpm in unstimulated
triplicate cultures) followed by standard deviation
Table 3 Immune responses against Giardia and control antigens as measured by the percentage of CD25CD26 positive CD4 T cells
by flow-cytometry
Exposed Unexposed p-values














(n= 19) vs PI-CFS/ICF
(n= 19)
Giardia ass A 10 μg/ml 8.6 (5.8) 10.3 (7.7) 8.8 (5.0) 12.4 (8.1) 1.8 (3.9) 0.001 ns*
Giardia ass B 10 μg/ml 3.1 (2.2) 4.3 (7.3) 3.7 (3.9) 7.9 (5.7) 1.9 (1.6) 0.009 ns*
Tuberculin (PPD)10 μg/ml 6.6 (5.4) 11.3 (11.1) 9.2 (11.4) 13.6 (5.2) 10.0 (13.6) ns ns*
LPS S. typi 1 μg/ml 5.2 (5.5) 5.2 (9.6) 4.5 (2.5) 5.1 (2.9) 3.0 (14.6) ns ns*
The values are percentages of activated CD4 T cells out of all CD4 T cells in stimulated cultures subtracted by the percentage of activated CD4 T cells in
unstimulated culture
*KruskalWallis test across all exposed groups was not significant (below p = 0.05). ns = not significant
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Table 4 Analyses of cytokines and sCD40L in supernatants of PBMC cultured for six days after stimulation with Giardia assemblage B
lysate in persons exposed to this pathogen in the Bergen 2004 outbreak with or without fatigue sequels, and in unexposed controls
Exposed Unexposed p-values










Exposed (n = 56)vs
unexposed (n = 10)
No PI-fatigue controls
(n = 20) vs PI-CFS/ICF
(n = 19)
IL-1b 8.4 (63.5) 23.7 (211) 10.0 (37.0) 37.3 (207) 0.8 (8.8) <0.001 ns*
IL-4 4.1 (6.6) 4.9 (4.8) -0.7 (7.4) 7.7 (5.6) 4.0 (29.4) 0.838 ns*
IL-6 496 (8364) 781 (18566) 957 (659) 741 (991) 85.3 (310) <0.001 ns*
IL-10 19.7 (23.3) 25.2 (354) 22.7 (13.2) 25.1 (5.9) 7.1 (25.3) <0.001 ns*
IFNy 1009 (3656) 1627 (4637) 775 (2569) 2577 (2322) 31.6 (956) <0.001 ns*
sCD40L 7.5 (25.0) 35.6 (59.0) 26.6 (27.3) 19.5 (53.5) 0.0 (43.2) 0.003 0.005
TNFa 192 (407) 346 (713) 213 (990) 395 (787) 7.6 (166) <0.001 ns*
IL-2 5.9 (9.3) 7.1 (8.1) 15.7 (15.1) 6.1 (8.9) 4.7 (4.6) 0.107 ns*
IL-9 11.7 (39.7) 23.5 (155) 20.3 (22.9) 23.6 (115) 2.8 (14.5) 0.018 ns*
IL-13 230 (203) 262 (212) 248 (371) 441 (272) 72.8 (100) 0.002 ns*
MIPa 51.1 (657) 112 (645) 252 (427) 692 (540) 15.5 (399) 0.034 ns*
MIPb 1691 (1856) 2306 (1939) 1754 (1618) 2862 (4195) 258 (1765) 0.034 ns*
TGFb1 -959 (2759) -2083 (2243) -1914 (1869) -2749 (3429) -3680 (1438) 0.033 ns*
TGFb2 -43.2 (61.7) 5.7 (46.4) 7.5 (111) 21.0 (45.0) -34.7 (61.1) 0.132 ns*
TGFb3 4.7 (23.0) -10.5 (19.3) -7.2 (8.3) -20.5 (15.3) -10.3 (43.0) 0.869 ns*
*KruskalWallis test across all exposed groups was not significant (below p = 0.05)
Values are pg/mL, median (SD) in stimulated cultures after subtracting measurements in unstimulated cultures. Values are given for analyte measurements that
were of sufficient quality for further analysis
Fig. 2 Levels of the costimulatory molecule sCD40L (CD154) found in supernatants of PBMC cultures after six days stimulation with Giardia assemblage B
lysate correlates with fatigue scores of participants by linear regression analysis (p= 0.001)
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and this could be a mechanism deserving further
research [19].
Few studies are available to compare our data with. In
line with the present study an analysis of specific
humoral immunity in PI-CFS after parvovirus B19 infec-
tion did not identify any pattern distinguishing this
illness [20]. Epstein-Barr virus specific cellular immune
responses have been investigated in a CFS patient group
of uncharacterized etiology, finding lower levels of
polyfunctional ebna-1 specific T cells, whereas no differ-
ences in cytomegalovirus-responses were detected [21].
Curriu et al. found general cellular proliferative
responses to be decreased in PBMCs from CFS patients
[22], possibly due to increased number of regulatory T
cells. We did observed a weaker proliferative response to
strong T cell activation with anti-CD3/anti-CD28 stimu-
lation in the CFS/ICF group, but these results were not
statistically significant. Additionally, we also observed
weaker, but non-significant, proliferative responses in
the other exposed groups.
Our patient cohort offered a rare chance to study
cellular immune responses to the eliciting pathogen. How-
ever, participants were recruited from a group of people
who had a common exposure five years previously, and
were therefore limited in number. We included those who
were willing to participate, and had no chance to expand
recruitment. From talking to individuals who did not wish
to participate we learned that many of these experienced a
substantial improvement in their condition between three
and five years after the outbreak.
There was a large variation observed in measurements,
causing large SDs. Some of this is likely due to the
multiplicative effect of even small differences after
culturing cells for six days.
The cytokine IL-17 which we have shown to play a
role in human memory responses against Giardia infec-
tions [23] had high background levels in supernatants in
the present study, leaving too few values measurable,
and could not be analyzed.
Examination at an earlier time point where we would
have been able to recruit more individuals still fulfilling
the CFS criteria into the study could have increased the
statistical power, and could possibly have resulted in
stronger, more distinct immune responses.
Conclusion
While these data confirm previous finding of T cell
memory responses towards Giardia and bring new data
on cytokine profiles, they did not reveal a difference in
the magnitude of Giardia-specific T cell responses with
respect to post-giardiasis CFS. Neither were differences
in the quality of these responses, as measured by cyto-
kine profiles in supernatants above Giardia stimulated
PBMCs, found, except for sCD40L being elevated in the
PI-CFS/ICF group as well as other exposed cases who
experienced fatigue after the outbreak Giardia assem-
blage B infection.
Additional file
Additional file 1: Table S1. Cultured PBMC supernatant analysis.
Analyses of cytokines and soluble CD40L in supernatants of PBMC
cultured for 6 days stimulated with Giardia lysates. (PDF 72 kb)
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